Lymphoma
PD-1 Checkpoint Inhibitors:
Harnessing the immune system to treat lymphomas
A new class of drugs, known as immune checkpoint inhibitors, is providing new perspective on how to treat relapsed
and refractory lymphomas, according to three abstracts
presented at the 56th ASH Annual Meeting.
“It has long been known that tumor cells induce an immunosuppressant microenvironment, which contributes to the failure of
patients to mount effective immune responses against their cancer,”
said John Gribben, MD, DSc, FMedSci, the chair of Medical Oncology at Barts Cancer Institute, Queen Mary University of London.
The programmed cell death 1 pathway is one such immune checkpo